{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:24:53Z","timestamp":1791559493334,"version":"4.3.4"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,9]]},"DOI":"10.7759\/cureus.114198","type":"journal-article","created":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T13:17:57Z","timestamp":1786281477000},"source":"Crossref","is-referenced-by-count":1,"title":["Beware the Ides of Chemotherapy: A Report on Hyperammonemic Encephalopathy Induced by FOLFOX-6 (5-Fluorouracil, Leucovorin, and Oxaliplatin)"],"prefix":"10.7759","author":[{"given":"Sudarsh","family":"TS","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sriram","family":"Balaji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dharani","family":"K","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krithika","family":"S","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthigeyan","family":"TS","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarav  J","family":"Paul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sahasyaa","family":"Adalarasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayaprakash","family":"N","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hariharan","family":"C","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1023\/a:1021989230535","article-title":"Pathophysiology of hepatic encephalopathy: a new look at ammonia","volume":"17","author":"Butterworth RF","year":"2002","unstructured":"Butterworth RF. Pathophysiology of hepatic encephalopathy: a new look at ammonia. Metab Brain Dis. 2002, 17:221-7. 10.1023\/a:1021989230535","journal-title":"Metab Brain Dis"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-010-1369-2","article-title":"Clinical practice: the management of hyperammonemia","volume":"170","author":"H\u00e4berle J","year":"2011","unstructured":"H\u00e4berle J. Clinical practice: the management of hyperammonemia. Eur J Pediatr. 2011, 170:21-34. 10.1007\/s00431-010-1369-2","journal-title":"Eur J Pediatr"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1074","article-title":"5-Fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley DB","year":"2003","unstructured":"Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003, 3:330-8. 10.1038\/nrc1074","journal-title":"Nat Rev Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/s0093-7754(03)00399-3","article-title":"Oxaliplatin-safety profile: neurotoxicity","volume":"30","author":"Grothey A","year":"2003","unstructured":"Grothey A. Oxaliplatin-safety profile: neurotoxicity. Semin Oncol. 2003, 30:5-13. 10.1016\/s0093-7754(03)00399-3","journal-title":"Semin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.3767","article-title":"Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy","volume":"26","author":"Gamelin L","year":"2008","unstructured":"Gamelin L, Boisdron-Celle M, Morel A, et al.. Oxaliplatin-related neurotoxicity: interest of calcium-magnesium infusion and no impact on its efficacy. J Clin Oncol. 2008, 26:1188-9. 10.1200\/JCO.2007.15.3767","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2010.116","article-title":"Mechanisms, diagnosis and management of hepatic encephalopathy","volume":"7","author":"Prakash R","year":"2010","unstructured":"Prakash R, Mullen KD. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol. 2010, 7:515-25. 10.1038\/nrgastro.2010.116","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.01.019","article-title":"5-Fluorouracil-induced hyperammonaemic encephalopathy: a French national survey","volume":"129","author":"Boil\u00e8ve A","year":"2020","unstructured":"Boil\u00e8ve A, Thomas L, Lillo-Le Lou\u00ebt A, et al.. 5-Fluorouracil-induced hyperammonaemic encephalopathy: a French national survey. Eur J Cancer. 2020, 129:32-40. 10.1016\/j.ejca.2020.01.019","journal-title":"Eur J Cancer"},{"key":"ref8","article-title":"Hyperammonemic coma presenting as Hashimoto's encephalopathy","volume":"56","author":"Adatia S","year":"2008","unstructured":"Adatia S, Poladia B, Joshi SR, Panikar V, Chauhan V, Hastak SM. Hyperammonemic coma presenting as Hashimoto's encephalopathy. J Assoc Physicians India. 2008, 56:989-91.","journal-title":"J Assoc Physicians India"},{"key":"ref9","article-title":"Valproate-induced hyperammonemic encephalopathy with normal liver function","volume":"53","author":"Rath A","year":"2005","unstructured":"Rath A, Naryanan TJ, Chowdhary GV, Murthy JM. Valproate-induced hyperammonemic encephalopathy with normal liver function. Neurol India. 2005, 53:226-8.","journal-title":"Neurol India"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.29011\/2574-7754.101803","article-title":"Unusual case of hyperammonemic encephalopathy in elderly patient without liver disease","volume":"9","author":"Palleschi L","year":"2024","unstructured":"Palleschi L, Paolantonio P, Galasso UG, et al.. Unusual case of hyperammonemic encephalopathy in elderly patient without liver disease. Ann Case Rep. 2024, 9:1803. 10.29011\/2574-7754.101803","journal-title":"Ann Case Rep"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.1422","article-title":"Hyperammonemic encephalopathy in a patient receiving fluorouracil\/oxaliplatin chemotherapy","volume":"6","author":"Ihoriya H","year":"2018","unstructured":"Ihoriya H, Yamamoto H, Yamada T, et al.. Hyperammonemic encephalopathy in a patient receiving fluorouracil\/oxaliplatin chemotherapy. Clin Case Rep. 2018, 6:603-5. 10.1002\/ccr3.1422","journal-title":"Clin Case Rep"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/CAD.0000000000000987","article-title":"Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible?","volume":"31","author":"Di Federico A","year":"2020","unstructured":"Di Federico A, Nuvola G, Sisi M, Lenzi B, Nobili E, Campana D. Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible?. Anticancer Drugs. 2020, 31:1103-5. 10.1097\/CAD.0000000000000987","journal-title":"Anticancer Drugs"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1159\/000481398","article-title":"Oxaliplatin-induced hyperammonemic encephalopathy in a patient with metastatic pancreatic cancer: a case report","volume":"10","author":"Ogata T","year":"2017","unstructured":"Ogata T, Satake H, Ogata M, Hatachi Y, Yasui H. Oxaliplatin-induced hyperammonemic encephalopathy in a patient with metastatic pancreatic cancer: a case report. Case Rep Oncol. 2017, 10:885-9. 10.1159\/000481398","journal-title":"Case Rep Oncol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.911","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update","volume":"103","author":"Amstutz U","year":"2018","unstructured":"Amstutz U, Henricks LM, Offer SM, et al.. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther. 2018, 103:210-6. 10.1002\/cpt.911","journal-title":"Clin Pharmacol Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/507983-beware-the-ides-of-chemotherapy-a-report-on-hyperammonemic-encephalopathy-induced-by-folfox-6-5-fluorouracil-leucovorin-and-oxaliplatin","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T13:17:58Z","timestamp":1786281478000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/507983-beware-the-ides-of-chemotherapy-a-report-on-hyperammonemic-encephalopathy-induced-by-folfox-6-5-fluorouracil-leucovorin-and-oxaliplatin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,9]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.114198","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,9]]}}}